Study highlights urinary biomarkers for meloxicam kidney injury in cats: full analysis

A newly published feline biomarker study points to urinary IGFBP-7 and KIM-1 as promising signals of meloxicam-induced kidney injury, adding fresh data to a long-running clinical problem: how to spot renal injury in cats before conventional markers rise. In the controlled study, repeated meloxicam exposure was associated with significantly higher urinary IGFBP-7 and KIM-1 in cats that developed renal injury, while urinary TIMP-2 was less reliable. (rex.libraries.wsu.edu)

The paper sits within a well-established safety context for meloxicam in cats. FDA says repeated meloxicam use in cats has been associated with acute renal failure and death, and that warning remains boxed on product labeling. At the same time, feline NSAID use is more nuanced than the warning alone might suggest: recent ISFM/AAFP guidance notes that meloxicam and robenacoxib are among the best-studied NSAIDs in cats, with safety and efficacy data in selected patients, including some with stable early CKD, underscoring how much careful patient selection and monitoring matter. (fda.gov)

The biomarker findings come from a toxin-induced model described by Washington State University investigators. Twelve healthy adult cats were enrolled, with treatment cats receiving meloxicam 0.3 mg/kg subcutaneously every 24 hours for 31 days and controls receiving saline. Four of six treated cats developed elevated serum creatinine and histopathologic evidence of renal injury. In those cats, the area under the curve for urinary IGFBP-7/creatinine and KIM-1/creatinine was significantly higher than in controls, while urinary TIMP-2 increased in only half of treated cats. (rex.libraries.wsu.edu)

That work also extends earlier findings from the same model on traditional renal markers. In the related Frontiers report, the investigators found insufficient evidence that serum SDMA outperformed creatinine for detecting impaired renal function caused by meloxicam-induced renal injury. Sampling in that study ran through day 47, and the time to azotemia was not significantly different when defined by creatinine versus SDMA. Taken together, the two papers strengthen the case that functional markers alone may miss or lag early tubular injury, which is exactly where urinary injury biomarkers could be useful. (frontiersin.org)

There’s also biologic plausibility behind the signal. KIM-1 has been characterized previously in cats and was detected in urine from cats with conditions associated with acute kidney injury, with expression localized to proximal tubular cells in affected kidneys. That prior work supports KIM-1 as a tubular injury marker in feline patients, rather than a one-off finding in this meloxicam model. Reference interval work for urinary KIM-1 in healthy cats has also begun to emerge, an important step if the marker is to move from research into broader clinical use. (academic.oup.com)

Expert reaction specifically to this new paper was limited in public sources, but the broader industry message is consistent: feline AKI needs better early detection tools. Reviews of feline AKI have noted that sensitive markers of early injury remain a gap, while consensus guidance on feline NSAID use emphasizes individualized prescribing, hydration status, comorbidities, and follow-up monitoring. Inference: this study is unlikely to change prescribing overnight, but it does add practical momentum to the search for renal biomarkers that can support safer analgesic use in cats. (pmc.ncbi.nlm.nih.gov)

Why it matters: For veterinarians, the key takeaway isn’t that meloxicam suddenly became riskier; that risk profile has been documented for years. The more important development is the possibility of earlier detection. If urinary IGFBP-7 and KIM-1 can identify injury before overt azotemia, clinicians may eventually have a better way to monitor higher-risk feline patients, investigate subtle renal stress, or refine decisions around ongoing NSAID therapy. That could be especially relevant in referral, emergency, anesthesia, pain management, and internal medicine settings where the tradeoffs around analgesia and renal risk are most acute. (fda.gov)

What to watch: The big questions now are clinical validation, commercial assay access, and whether these biomarkers perform in everyday patients with concurrent disease, dehydration, or mixed causes of AKI, not just in an experimental model. Until then, the study is best read as an encouraging signal, not a practice-changing test rollout. (rex.libraries.wsu.edu)